Form 4: Framework Ventures Boosts NovaBay Pharmaceuticals Stake

Framework Ventures entities significantly increased their beneficial ownership in NovaBay Pharmaceuticals through preferred stock conversions and pre-funded warrant acquisitions.

Summary

• Framework Ventures IV L.P. converted 220,663 shares of NovaBay's Series D Non-Voting Convertible Preferred Stock into 35,306,080 shares of Common Stock.
• Framework Ventures IV L.P. also converted 134,375 shares of NovaBay's Series E Non-Voting Convertible Preferred Stock into 21,500,000 shares of Common Stock.
• These conversions, totaling 56,806,080 shares of Common Stock, occurred on October 21, 2025, following stockholder approval at the annual meeting on October 16, 2025.
• Framework Ventures IV L.P. acquired 2,702,703 pre-funded warrants to purchase NovaBay Common Stock on October 16, 2025.
• The purchase price for these pre-funded warrants was $1.10 per warrant, representing 110% of the prior day's closing price less the $0.01 exercise price.
• The reporting persons, including Framework Ventures IV L.P., Framework Ventures Management LLC, Framework Ventures IV GP LLC, Vance Spencer, and Michael Ernest Anderson, are identified as Directors and 10% Owners of NovaBay Pharmaceuticals, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in beneficial ownership by a major investor and director group, which can be interpreted as a vote of confidence. The conversion of preferred stock simplifies the capital structure for these holdings, and the acquisition of warrants provides future upside potential.

Positives

• Significant increase in beneficial ownership by Framework Ventures entities, who are also directors and 10% owners, signaling a strong vote of confidence in NovaBay Pharmaceuticals.
• The conversion of preferred stock into common stock simplifies the capital structure for these holdings.
• The acquisition of pre-funded warrants provides future upside potential for the investor group.

Risks

• The pre-funded warrants are exercisable for shares of Common Stock at any time after January 1, 2026, subject to future stockholder approval.

Future Outlook

Pre-funded warrants acquired by Framework Ventures IV L.P. will become exercisable after January 1, 2026, contingent upon receiving future stockholder approval.

Industry Context

This filing details a significant insider ownership change for NovaBay Pharmaceuticals, a common occurrence in the biotechnology/pharmaceutical sector as investors adjust their holdings or convert existing instruments. Such transactions are closely watched by the market for signals of insider confidence.

Corporate Governance

Related Party Transactions

• Framework Ventures IV L.P., an entity associated with directors Vance Spencer and Michael Ernest Anderson and a 10% owner, converted 220,663 shares of Series D Preferred Stock into 35,306,080 shares of Common Stock.
• Framework Ventures IV L.P. also converted 134,375 shares of Series E Preferred Stock into 21,500,000 shares of Common Stock.
• Framework Ventures IV L.P. acquired 2,702,703 pre-funded warrants from NovaBay Pharmaceuticals, Inc. for a purchase price of $1.10 per warrant (less a $0.01 exercise price).

Stakeholder Impact

• Shareholders: The significant increase in beneficial ownership by a major investor and director group could be viewed positively, potentially signaling confidence. The conversion of preferred stock into common stock increases the outstanding common share count.
• Company: The issuance of pre-funded warrants provided capital to the company and strengthens the relationship with a key investor and director group.

Next Steps

• Stockholder approval will be required for the pre-funded warrants to become exercisable after January 1, 2026.

Key Dates

Recommendation

The filing indicates a significant increase in beneficial ownership by Framework Ventures entities, who are also directors and 10% owners. This insider activity, involving the conversion of preferred stock into common shares and the acquisition of pre-funded warrants, suggests a vote of confidence in NovaBay Pharmaceuticals. However, without additional financial performance data or strategic updates, a 'hold' recommendation is prudent, as this filing primarily reports compliance-driven transactions rather than new operational insights.

Keywords

NovaBay Pharmaceuticals, NBY, Framework Ventures, beneficial ownership, Form 4, insider trading, preferred stock conversion, pre-funded warrants, equity, director ownership